Ad
related to: cariprazine brand name and product classification guidelines for drug- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
Search results
Results from the WOW.Com Content Network
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, [8] which is used in the treatment of schizophrenia, bipolar mania, [9] bipolar depression, [10] and as an add-on therapy for major depressive disorder. [6]
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; ... Cariprazine: Vraylar: N05AX15 Carpipramine: Prazinil, Defekton:
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
For premium support please call: 800-290-4726 more ways to reach us
Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. [1] They act by antagonizing the α 2 -adrenergic receptor and certain serotonin receptors such as 5-HT 2A and 5-HT 2C , [ 1 ] but also 5-HT 3 , [ 1 ] 5-HT 6 , and/or 5-HT 7 in some cases.
Note: "Notable" is to mean side-effects that are particularly unique to the antipsychotic drug in question. For example, clozapine is notorious for its ability to cause agranulocytosis. If data on the propensity of a particular drug to cause a particular AE is unavailable an estimation is substituted based on the pharmacologic profile of the drug.
Typical antipsychotics (also known as major tranquilizers, and first generation antipsychotics) are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis (in particular, schizophrenia). Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions.
A Prescription Drug User Fee Act (PDUFA) action date is set for August 31, 2025. The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously ...
Ad
related to: cariprazine brand name and product classification guidelines for drug- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
